Early Increase in Autoantibodies Against Human Oxidized Low-Density Lipoprotein in Hypertensive Patients After Blood Pressure Control
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
20/10/2012
20/10/2012
2010
|
Resumo |
BACKGROUND Oxidized lipoproteins and antioxidized low-density lipoprotein (anti-oxLDL) antibodies (Abs) have been detected in plasma in response to blood pressure (BP) elevation, suggesting the participation of the adaptive immune system. Therefore, treatment of hypertension may act on the immune response by decreasing oxidation stimuli. However, this issue has not been addressed. Thus, we have here analyzed anti-oxLDL Abs in untreated (naive) hypertensive patients shortly after initiation of anti hypertensive therapeutic regimens. METHODS Titers of anti-oxLDL Abs were measured in subjects with recently diagnosed hypertension on stage 1 (n = 94), in primary prevention of coronary disease, with no other risk factors, and naive of anti hypertensive medication at entry. Subjects were randomly assigned to receive perindopril, hydrochlorothiazide (HCTZ), or indapamide (INDA) for 12 weeks, with additional perindopril if necessary to achieve BP control. Abs against copper-oxidized LDL were measured by enzyme-linked immunosorbent assay. RESULTS Twelve-week antihypertensive treatment reduced both office-based and 24-h ambulatory BP measurements (P < 0.0005). The decrease in BP was accompanied by reduction in thiobarbituric acid-reactive substances (TBARS) (P < 0.05), increase in anti-oxLDL Ab titers (P < 0.005), and improvement in flow-mediated dilation (FMD) (P < 0.0005), independently of treatment. Although BP was reduced, we observed favorable changes in anti-oxLDL titers and FMD. CONCLUSIONS We observed that anti-oxLDL Ab titers increase after antihypertensive therapy in primary prevention when achieving BP targets. Our results are in agreement with the concept that propensity to oxidation is increased by essential hypertension and anti-oxLDL Abs may be protective and potential biomarkers for the follow-up of hypertension treatment. FAPESP (The State of Sao Paulo Research Foundation) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) The National Institute of Science and Technology of Complex Fluids (INCT-FCx) The National Institute of Science and Technology of Complex Fluids (INCT-FCx) The National Institute of Science and Technology-Nanomaterials for Integrated Markers (INCT-IINAMI) The National Institute of Science and Technology-Nanomaterials for Integrated Markers (INCT-IINAMI) CAPES (National Counsel of Technological and Scientific Development) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) |
Identificador |
AMERICAN JOURNAL OF HYPERTENSION, v.23, n.2, p.208-214, 2010 0895-7061 http://producao.usp.br/handle/BDPI/29123 10.1038/ajh.2009.214 |
Idioma(s) |
eng |
Publicador |
NATURE PUBLISHING GROUP |
Relação |
American Journal of Hypertension |
Direitos |
restrictedAccess Copyright NATURE PUBLISHING GROUP |
Palavras-Chave | #angiotensin-converting enzyme inhibitor #antibodies #blood pressure #diuretic #hypertension #oxidized LDL #JOINT NATIONAL COMMITTEE #CORONARY-ARTERY-DISEASE #ANGIOTENSIN-II #BORDERLINE HYPERTENSION #UNSTABLE ANGINA #OXIDATIVE MODIFICATION #MODIFIED LDL #TASK-FORCE #ANTIBODIES #ATHEROSCLEROSIS #Peripheral Vascular Disease |
Tipo |
article original article publishedVersion |